Selumetinib CAS 606143-52-6

Selumetinib CAS 606143-52-6

Identification

CAS Number

606143-52-6

Name

Selumetinib CAS 606143-52-6

Synonyms

1H-Benzimidazole-6-carboxamide, 5-[(4-bromo-2-chlorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl- [ACD/Index Name]
5-[(4-Brom-2-chlorphenyl)amino]-4-fluor-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazol-6-carboxamid [German] [ACD/IUPAC Name]
5-[(4-bromo-2-chlorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-1,3-benzodiazole-6-carboxamide
5-[(4-Bromo-2-chlorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide [ACD/IUPAC Name]
5-[(4-Bromo-2-chlorophényl)amino]-4-fluoro-N-(2-hydroxyéthoxy)-1-méthyl-1H-benzimidazole-6-carboxamide [French] [ACD/IUPAC Name]
606143-52-6 [RN]
6UH91I579U
selumetinib [INN] [USAN] [Wiki]
selumetinib [Spanish] [INN]
sélumétinib [French] [INN]
selumetinibum [Latin] [INN]
1777807-55-2 [RN]
1H-Benzimidazole-6-carboxamide, 5-[(4-bromo-2-chlorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl
3EW
5-((4-bromo-2-chlorophenyl)amino)-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzo[d]imidazole-6-carboxamide
5-(4-Bromo-2-chlorophenylamino)-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzo[d]imidazole-6-carboxamide
6-(4-bromo-2-chloroanilino)-7-fluoro-N-(2-hydroxyethoxy)-3-methyl-5-benzimidazolecarboxamide
6-(4-bromo-2-chloroanilino)-7-fluoro-N-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamide
6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide
6-(4-Bromo-2-chlorophenylamino)-7-fluoro-N-(2-hydroxyethoxy)-3-methyl-3H-benzo[d]imidazole-5-carboxamide
6-[(4-bromo-2-chlorophenyl)amino]-7-fluoro-N-(2-hydroxyethoxy)-3-methyl-5-benzimidazolecarboxamide
6-[(4-bromo-2-chlorophenyl)amino]-7-fluoro-N-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamide
6-[(4-bromo-2-chloro-phenyl)amino]-7-fluoro-N-(2-hydroxyethoxy)-3-methyl-benzimidazole-5-carboxamide
Array142886
AZD6244, ARRY-142886, ARRY-886
CHEMBL1614701
D09666
MAP2K1
MFCD11977472 [MDL number]
sélumétinib
Selumetinib (USAN/INN)
selumetinibum
UNII:6UH91I579U
UNII-6UH91I579U
селуметиниб [Russian]

SMILES

Cn1cnc2c1cc(c(c2F)Nc3ccc(cc3Cl)Br)C(=O)NOCCO

StdInChI

InChI=1S/C17H15BrClFN4O3/c1-24-8-21-16-13(24)7-10(17(26)23-27-5-4-25)15(14(16)20)22-12-3-2-9(18)6-11(12)19/h2-3,6-8,22,25H,4-5H2,1H3,(H,23,26)

StdInChIKey

CYOHGALHFOKKQC-UHFFFAOYSA-N

Molecular Formula

C17H15BrClFN4O3

Molecular Weight

457.681

EINECS

207-313-3

MDL Number

MFCD11977472

Properties

Appearance

White or off-white powder.

Safety Data

Symbol

exclamation-mark-jpgexclamation-mark-jpgGHS07, GHS08

Signal Word

Warning

Hazard statements

H302 – H317 – H361f – H373 – H413

Precautionary Statements

P202 – P273 – P280 – P301 + P312 – P302 + P352 – P308 + P313

WGK Germany

3

MSDS Download

Specifications and Other Information of Our

Identification Methods

Purity

99% min

Water

0.5%max

RESIDUE ON IGNITION

0.2 %max

Ethyl acetate

≤5000ppm

Methanol

≤5000ppm

Dichloromethane

≤600ppm

THF

≤500ppm

Petroleum ether

≤5000ppm

Shelf Life

2 years

Storage

Under room temperature away from light

Known Application

The anti-cancer drug Selumetinib (1), developed by the British company AstraZeneca, is used for the treatment of advanced non-small cell lung cancer (NSCLC). Selumetinib primarily inhibits the growth of various tumors, including melanomas with B-Raf mutations and non-small cell lung cancer (NSCLC) with K-Ras mutations, by regulating the key protein kinase MEK in the Ras-Raf-MEK-ERK pathway. It is mainly employed in the treatment of diseases such as cholangiocarcinoma, colorectal cancer, and NSCLC. Currently, Selumetinib is in phase III clinical trials for the treatment of non-small cell lung cancer.

General View of Documents

This product is sold exclusively through our sales company Watson International Limited, and please click the link below for details (https://www.watson-int.com/).